Decoy Therapeutics Inc.
DCOY evidence brief
What we can confirm
- BioSniper Score:
- 4.6 / 10
- Market Cap:
- $1.7M
- Lead Asset:
- cov (Preclinical)
What it means
What to watch
Prepared research question
What matters most for DCOY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DCOY
Decoy Therapeutics Inc. (DCOY) is a pre-clinical stage biotechnology company formed via a January 2026 merger, developing Designable Multi-Antivirals (D-MAVs) through its proprietary IMP³ACT platform and holding legacy small-molecule oncology candidates [sec_mda · as of 2026-08-12].
Key risk: Pre-clinical stage
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$1.7M
Cash Runway
—
Lead Asset
cov (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Decoy Therapeutics Inc..
Decoy Therapeutics Inc. (DCOY) is a pre-clinical stage biotechnology company formed via a January 2026 merger, developing Designable Multi-Antivirals (D-MAVs) through its proprietary IMP³ACT platform and holding legacy small-molecule oncology candidates [sec_mda · as of 2026-08-12].
- Formed via a merger in January 2026, with shares now trading under symbol DCOY on Nasdaq [sec_mda · as of 2026-08-12].
- Lead program DCOY-CoV reported preclinical PK data supporting once-weekly intranasal dosing as of September 2026 [news · published 2026-09-29].
- Cash & equivalents of $8.3M as of 2026-06-30, with net income of -$2.4M for the same period [sec].
- Pipeline includes D-MAV candidates for respiratory viruses and two legacy small-molecule oncology assets (SP-3164 and SP-2577) [sec_mda · as of 2026-08-12].
- Raised approximately $3.5M in gross proceeds from a private placement as of the closing date, with potential additional $7.0M from milestone warrants [sec_mda · as of 2026-08-12].
What works
- Proprietary IMP³ACT platform uses ML/AI and high-speed synthesis to rapidly engineer peptide conjugates, potentially enabling a pipeline that can be extended rather than rebuilt for new threats [sec · filed 2026-07-10].
- Lead DCOY-CoV program achieved preclinical PK data supporting once-weekly intranasal dosing, which could offer a dosing advantage over daily alternatives [news · published 2026-09-29].
- Legacy small-molecule candidates SP-3164 and SP-2577 have received FDA fast track designation for Ewing sarcoma, a rare pediatric disease [sec_mda · as of 2026-08-12].
What to weigh
- Company is pre-clinical stage with minimal revenue ($0.2M as of 2026-06-30) and negative net income (-$2.4M), indicating heavy reliance on external funding [sec].
- Cash position of $8.3M as of 2026-06-30 is limited for a biotech needing to fund clinical trials and operations, and the company acknowledges it will need to raise substantial additional capital [sec · filed 2026-08-04].
- Legacy oncology programs (SP-3164, SP-2577) have no further enrollment planned and the company intends to seek strategic alternatives, indicating potential discontinuation [sec · filed 2026-06-15].
From the filings
Quoted directly from source documents.
Company is pre-clinical stage and needs additional capital
“We are a pre-clinical stage biotechnology company focused on advancing our pipeline of peptide conjugate therapeutics engineered through our proprietary IMP3ACT™ platform.”
SEC filings · July 10, 2026
Lead program DCOY-CoV shows once-weekly intranasal dosing potential
“Results demonstrate that a single intranasal dose maintains therapeutic drug concentrations in both upper respiratory mucosal tissues and deep lung tissue for up to seven days.”
News · September 29, 2026
Private placement raised $3.5M with potential additional $7.0M
“we received gross proceeds of approximately $3.5 million from this private placement”
SEC MD&A · August 12, 2026
Risks & what to watch (4)›
Key risks
- Pre-clinical stage — No approved products; all programs are in pre-clinical or early clinical development, with no guarantee of success [sec · filed 2026-07-10].
- Limited cash runway — Cash of $8.3M as of 2026-06-30 may be insufficient to fund operations and clinical trials without additional capital [sec].
- Dependence on milestone warrants — Additional funding of up to $7.0M from warrants is contingent on shareholder approval and achieving clinical milestones [sec_mda · as of 2026-08-12].
- Legacy program uncertainty — Oncology candidates SP-3164 and SP-2577 have no further enrollment planned and are being evaluated for strategic alternatives [sec · filed 2026-06-15].
What to watch
- Initiation of clinical trials for lead DCOY-CoV program, as the company intends to use private placement proceeds to advance it [sec_mda · as of 2026-08-12].
- Shareholder vote on warrant exercise proposal, which could unlock up to $7.0M in additional funding [sec · filed 2026-08-04].
- Strategic decisions regarding legacy oncology assets SP-3164 and SP-2577 [sec · filed 2026-06-15].
- Any further preclinical or clinical data updates for the D-MAV pipeline [news · published 2026-09-29].
Sources: News · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Decoy Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Decoy Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.08 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$11K
| Holder | Shares | Value |
|---|---|---|
| tower research capital llc (trc) | 1,021 | $7K |
| ubs group ag | 546 | $4K |
| advisory services network, llc | 41 | $268 |
| morgan stanley | 1 | $7 |
Short Interest
as of May 20, 2026- % of float
- 4.4%
- Days to cover
- 0.8
- Shares short
- 23,252
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DCOY short interestGovernance
Frequently asked questions
What is the AI investment thesis for Decoy Therapeutics Inc.?
Decoy Therapeutics Inc. (DCOY) is a pre-clinical stage biotechnology company formed via a January 2026 merger, developing Designable Multi-Antivirals (D-MAVs) through its proprietary IMP³ACT platform and holding legacy small-molecule oncology candidates [sec_mda · as of 2026-08-12].
What is Decoy Therapeutics Inc.'s lead drug candidate?
Decoy Therapeutics Inc.'s most advanced tracked candidate is cov (Preclinical) for Pan-Coronavirus prophylactic for immunocompromised patients.
Who is the CEO of Decoy Therapeutics Inc.?
Mr. Frederick E. Pierce II is the chief executive officer of Decoy Therapeutics Inc. (DCOY).
Where is Decoy Therapeutics Inc. headquartered?
Decoy Therapeutics Inc. (DCOY) is headquartered in Houston, TX, United States.
What therapeutic areas does Decoy Therapeutics Inc. focus on?
Decoy Therapeutics Inc. develops therapies across Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.